Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients

Hilmani, S.; Abidi, Omar; Benrahma, Houda; Karkouri, Mehdi; Sahraoui, S.; Azhari, A. El; Barakat, Abdelhamid

doi:10.1007/s12031-012-9868-4

Cited by 10 publications

(9 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, glial tumors in Moroccan population have not been investigated, except one study involving molecular analyses of TP53 and IDH1/2 genes in 34 primary glioblastoma cases with no mutation identified in IDH1/2 genes [39]. This study is complementary to the first Moroccan study and whose results are consistent with those of international literature.…”

Section: Discussionsupporting

confidence: 68%

EGFRAmplification andIDHMutations in Glioblastoma Patients of the Northeast of Morocco

Senhaji

Louati

Chbani

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Glioblastomas are the most frequent and aggressive primary brain tumors which are expressing various evolutions, aggressiveness, and prognosis. Thus, the 2007 World Health Organization classification based solely on the histological criteria is no longer sufficient. It should be complemented by molecular analysis for a true histomolecular classification. The new 2016 WHO classification of tumors of the central nervous system uses molecular parameters in addition to histology to reclassify these tumors and reduce the interobserver variability. The aim of this study is to determine the prevalence of IDH mutations and EGFR amplifications in the population of the northeast region of Morocco and then to compare the results with other studies. Methods. IDH1 codon 132 and IDH2 codon 172 were directly sequenced and the amplification of exon 20 of EGFR gene was investigated by qPCR in 65 glioblastoma tumors diagnosed at the University Hospital of Fez between 2010 and 2014. Results. The R132H IDH1 mutation was observed in 8 of 65 tumor samples (12.31%). No mutation of IDH2 was detected. EGFR amplification was identified in 17 cases (26.15%). Conclusion. A systematic search of both histological and molecular markers should be requisite for a good diagnosis and a better management of glioblastomas.

show abstract

Section: Discussionsupporting

confidence: 68%

EGFRAmplification andIDHMutations in Glioblastoma Patients of the Northeast of Morocco

Senhaji

Louati

Chbani

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Indeed, younger age, good Karnofsky performance status (KPS) at the time of diagnosis, radiotherapy, histology and extent of tumor resection have been identified as potential prognostic factors for patients with GBM [5,[11][12][13][14][15][16][17][18] . In a previous study, we analyzed TP53 and IDH1-2 genes in 34 GBM cases [19] . Here we attempted to clarify the prognostic value of some clinical, therapeutic and tumor parameters noted in Moroccan GBM patients.…”

mentioning

confidence: 99%

Prognostic factors of survival in Moroccan patients with Glioblastoma

Hilmani¹,

Barakat²,

Kamar³

et al. 2014

JST

Self Cite

View full text Add to dashboard Cite

Background: Glioblastoma is the most common and aggressive type of glioma and has the poorest survival. Some parameters have been identified as potential prognostic factors for patients with glioblastoma. The purpose of this study is to examine the influence of clinical, tumor and treatment factors on overall survival in Moroccan patients with newly diagnosed glioblastoma. Methods: In this study, we retrospectively analyzed data from 89 Moroccan patients with newly diagnosed Glioblastoma (54 males and 35 females). The effect of different prognostic factors on survival was evaluated using Kaplan-Meier method and log rank test for univariate analysis; and Cox regression method for multivariate analysis to identify the independent prognostic factors. Results: The Median age of patients at diagnosis was 52 years (range 11-84 years) and the male/female ratio was 1.54/1. The median of pre-operative Karnofsky Performance Score (KPS) was 70 (95% CI: 60-70) and the median overall survival was 12 months (95%: 9-13 months). According to univariate analysis, age (p = 0.0088), KPS (p = 0.0001) and radiation treatment (p < 0.0001) parameters were significantly associated with survival. In addition, the tumor size, KPS and radiotherapy parameters were significantly associated with survival in multivariate Cox analysis (p < 0.05). However, extent of tumor resection, gender, chemotherapy and clinical history delay factors were not found significant in both analyses (p > 0.05). Conclusion: Our results showed the strong prognostic value of age, performance score, and treatment with radiotherapy for glioblastoma patients validating the results published in previous studies. This work could contribute towards informing further research on prognostic variables for patients with glioblastoma.

show abstract

“…It was reported in these selected articles, after sequencing of 65 and 62 patients in two different studies performed by Senhaji et al, the IDH 1 gene mutation (codons 132) was found in 12.36% and 36.75% of patients with glioblastoma (Senhaji et al, 2017, Senhaji et al, 2016). On the other hand, the study of Hilmani et al reported that there is no IDH 1 gene mutation among 34 patients with primary glioblastoma (Hilmani et al, 2013).…”

Section: Resultsmentioning

confidence: 97%

“…Loss of the p53 gene in GBM is due to mutations in exons 5 and exon 8 or homozygous/heterozygous deletion of chromosome 17 (Nagpal et al, 2006). The mutations affected exon 8 of the p53 gene are missense at R273H (818 G > A), and nonsense at R306X (916 C > T).The other mutation in exon 5 localized at Q136X (406C > T) (Hilmani et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Genetics of Glioblastoma in Moroccan population: Review of literature

et al. 2018

View full text Add to dashboard Cite

Glioblastoma is the most aggressive malignant type of central nervous system tumors. The literature review revealed that the most common genetic abnormalities in primary and secondary glioblastomas are IDH1 / 2 mutations, p53 mutations, and overexpression of EGFR.To our knowledge, this is the first Moroccan study to provide a global picture of genetic studies performed on Moroccan patients to describe genetic markers and their frequency in our population.An in-depth research in ScienceDirect and Pubmed on glioblastoma articles treated in Morocco, this research is based on the following keywords: glioblastoma in Morocco, primary glioblastoma in Morocco, secondary glioblastoma in Morocco.We found only three research articles on genomic alteration of IDH1 / 2, p53 and EGFR expression. The frequency of these gene mutations in our population was similar to those reported from other populations.Additional molecular studies need to be performed on other genes to describe other genetic markers in the Moroccan population.

show abstract

Clinicopathological Features and Molecular Analysis of Primary Glioblastomas in Moroccan Patients

Cited by 10 publications

References 45 publications

EGFRAmplification andIDHMutations in Glioblastoma Patients of the Northeast of Morocco

EGFRAmplification andIDHMutations in Glioblastoma Patients of the Northeast of Morocco

Prognostic factors of survival in Moroccan patients with Glioblastoma

Genetics of Glioblastoma in Moroccan population: Review of literature

Contact Info

Product

Resources

About